GRCL News and Press, Gracell Biotechnologies Inc. From 04/10/21

Gracell Biotechnologies Reports Long-term Follow-up Data on TruUCAR-enabled GC027 in Relapsed/Refractory T-ALL at the AACR 2021 Annual Meeting PR Newswire SUZHOU and SHANGHAI, China , April 10, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL)...

SUZHOU, China and SHANGHAI, China, April 05, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies, today anno...

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. The holiday-shortened week saw tech suddenly back in favor after a first quarter where cyclical and value plays dominated. The Nasdaq, which ...

Gracell Biotechnologies (GRCL) has signed a Manufacturing Service Agreement with Lonza (LZAGY) for clinical manufacturing of Gracell's CAR-T cell product candidates in the U.S.Lonza is an ‘ideal strategic collaborator for advancing our pioneering, proprietary FasTCAR platform...

Gracell Biotechnologies Signs Agreement with Lonza to Manufacture Gracell's FasTCAR Product Candidates in the U.S. The collaboration will help Gracell leverage Lonza's worldwide integrated services and expertise in CAR-T cell therapy manufacturing PR Newswire SUZHOU,...

Gracell Biotechnologies Announces Enrollment of First Patient in Registrational Phase 1/2 Clinical Study for GC007g, an Allogeneic CAR-T Cell Therapy for the Treatment of Relapsed or Refractory B-ALL PR Newswire SUZHOU and SHANGHAI, China , March 31, 2021 /PRNews...

SUZHOU and SHANGHAI, China, March 17, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies, today announced t...

Gracell Biotechnologies, Inc. (GRCL) Q4 2020 Earnings Conference Call March 10, 2021 08:00 AM ET Company Participants Kevin Xie - Chief Financial Officer Dr. William Cao - Founder and Chief Executive Officer Dr. Martina Sersch - Chief Medical Officer Conference Call Participants Mohit Bansal ...

Gracell Biotechnologies (GRCL): Q4 GAAP EPS of -$0.42 misses by $0.32.As of December 31, 2020, we had $118.5M in cash and cash equivalents and short-term investments.Press Release For further details see: Gracell Biotechnologies EPS misses by $0.32

Reported interim readouts for lead CAR-T product candidates: FasTCAR-enabled dual-targeting BCMA/CD19 autologous CAR-T product candidate GC012F for the treatment of multiple myeloma and TruUCAR-enabled CD7-directed CAR-T product candidate GC027 for the treatment of T-ALL Completed...